Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arthrelis
- Development stage
- Unknown
- Lead developer
- PKMed
- Modality
- Small Molecules
- Administration
- Intraarticular
01
Overview
Arthrelis (PKM-01) is an investigational, dual-action, intra-articular injectable therapy developed by PK MED for the treatment of refractory gout flares. It is formulated as a sustained-release micro-implant using a polylactic-co-glycolic acid (PLGA) matrix polymer to deliver a combination of colchicine, a potent anti-inflammatory agent, and ropivacaine, a local anesthetic. By providing localized, controlled release of colchicine directly into the joint, Arthrelis aims to achieve powerful anti-inflammatory effects while minimizing the systemic exposure and toxicity associated with oral colchicine. Concurrently, the anesthetic action of ropivacaine provides rapid pain relief. The program has received FDA clearance to proceed directly into Phase 2 clinical trials.
- Other names
- Arthreliscolchicine + ropivacaine
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Arthrelis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arthrelis.